Single-dose neonatal gene therapy preserves motor coordination and extends survival of Polg-deficient mice
In the authors' words
POLG mutations are the most common single nuclear gene cause of mitochondrial disease. POLG disease spans a spectrum of clinical presentations with variable age of onset and severity. Early-onset disease is often severe and fatal (e.g., Alpers syndrome, myocerebrohepatopathy), while late-onset disease can be relatively mild (e.g., progressive external ophthalmoplegia). POLG disease is incurable, with few symptomatic treatments available, none of which can prevent its progression. Gene replacement therapy has the potential to halt or prevent POLG disease, but its development has been hindered by the large size of the POLG cDNA and the scarcity of suitable mouse models. Here, we developed a bespoke Polg knockout (KO) mouse model by inactivating the Polg locus in parvalbumin-expressing neurons (e.g., Purkinje cells) and fast-twitch skeletal muscle fibers. KO mice developed progressive motor coordination deficits, respiratory chain deficiency in Purkinje cells and skeletal muscle, and died prematurely. We also developed nine AAV-based gene therapy vectors and confirmed their ability to deliver and express the human POL{gamma}A protein in different mouse tissues. A single high-dose administration of either of two lead candidates into Polg KO neonates preserved respiratory chain activity in Purkinje cells and skeletal muscle, delayed the onset of motor coordination deficits, and extended lifespan. Thus, our work provides preclinical proof of concept for gene replacement therapy for POLG disease, establishing the feasibility of this approach and laying the foundation for further development in the field.
Appeared: Thursday, November 19. bioRxiv. Preprint, not yet peer-reviewed.